Tislelizumab has previously demonstrated a high complete response rate regardless of FcγRΙ-expressing Mφ abundance in the classical Hodgkin lymphoma TME [41, 42], further supporting the lack of a negative effect of CD64+ Mφ infiltration on the anti-tumor activity of tislelizumab. Here, FCGR2A is linked to Hodgkins lymphoma.